BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

Core Insights - BioCryst Pharmaceuticals announced new data on ORLADEYO® (berotralstat) for hereditary angioedema (HAE) treatment to be presented at the EAACI meeting in Valencia, Spain from May 31 to June 3, 2024 [1] Group 1: Product Information - ORLADEYO® (berotralstat) is the first and only oral therapy specifically designed to prevent HAE attacks in patients aged 12 years and older [2] - The drug works by decreasing the activity of plasma kallikrein, with a recommended dosage of one capsule per day [2] Group 2: Clinical Data Presentation - Two abstracts will be presented at the EAACI meeting: 1. Adverse Health Outcomes and Patient and Physician Perspectives of Attenuated Androgen Use in HAE [1] 2. Effectiveness and Safety of Berotralstat in Patients with HAE with Normal C1 Inhibitor: A European Case Series [1] Group 3: Safety Information - ORLADEYO is indicated for prophylaxis to prevent HAE attacks but not for the treatment of acute attacks [3][4] - Common adverse reactions include abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease [5] - A reduced dosage of 110 mg is recommended for patients with moderate or severe hepatic impairment [5]